Otsuka Pharm Co Ltd patents expiration
1. Abilify Maintena Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8993761 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 3 days ago) | |
| US8399469 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(1 year, 8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089567 | OTSUKA PHARM CO LTD | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 7 months ago) | |
| US8338428 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(a month ago) | |
| US8759351 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(a month ago) | |
| US7807680 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 21 days from now) | |
| US8030313 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 21 days from now) | |
| US8722679 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 21 days from now) | |
| US8338427 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Mar, 2025
(1 year, 5 months from now) | |
| US11400087 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US10980803 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US11154553 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US11344547 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(10 years from now) | |
| US11648347 | OTSUKA PHARM CO LTD | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient |
Apr, 2034
(10 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Use of aripiprazole in extended release injectable suspension; Tr...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic